Overview

Phase I Trial of an Investigational Small Pox Medication

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
SIGA Technologies
Collaborator:
National Institutes of Health (NIH)